Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Evercore ISI set a $635.00 price target on Regeneron Pharmaceuticals in a research note on Monday, June 20th. Barclays increased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 12th. Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $635.00 to $645.00 and gave the company a "market perform" rating in a report on Wednesday, July 20th. StockNews.com cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, July 26th. Finally, Jefferies Financial Group cut shares of Regeneron Pharmaceuticals to a "sell" rating and set a $536.00 target price for the company. in a research note on Friday, June 17th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $697.85.

Regeneron Pharmaceuticals Trading Up 2.7 %

Regeneron Pharmaceuticals stock traded up $16.68 during mid-day trading on Monday, hitting $630.29. 23,120 shares of the company's stock were exchanged, compared to its average volume of 695,719. The company's 50 day simple moving average is $598.47 and its 200-day simple moving average is $636.26. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $68.41 billion, a P/E ratio of 12.25, a PEG ratio of 1.97 and a beta of 0.29. Regeneron Pharmaceuticals has a fifty-two week low of $538.01 and a fifty-two week high of $747.42.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Rating) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.94 by ($0.17). The business had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. The firm's revenue was down 44.4% compared to the same quarter last year. During the same quarter last year, the company earned $27.97 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 38.89 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,100 shares of the firm's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $581.53, for a total transaction of $639,683.00. Following the sale, the executive vice president now directly owns 19,644 shares in the company, valued at $11,423,575.32. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.99% of the stock is owned by insiders.